| ARCA biopharma is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases. Co.'s key product candidate, Gencaro (bucindolol hydrochloride), is an investigational pharmacological beta-blocker and mild vasodilator that Co. is developing for the potential treatment of patients with chronic heart failure with reduced left ventricular ejection fraction, who also have atrial fibrillation (AF), or at risk of developing AF. Co. also has pharmacogenetic and other patent rights to drug candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. The ABIO YTD return is shown above.
The YTD Return on the ABIO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ABIO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABIO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.